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a  b  s  t  r  a  c  t
Machrophage activation syndrome (MAS) is a rare and potentially fatal disease, com-
monly associated with chronic rheumatic diseases, mainly juvenile idiopathic arthritis.
It  is included in the group of secondary forms of haemophagocytic syndrome, and other
causes are lymphoproliferative diseases and infections. Its most important clinical and
laboratorial manifestations are non-remitting fever, splenomegaly, bleeding, impairment
of  liver function, cytopenias, hypoalbuminemia, hypertriglyceridemia, hypoﬁbrinogenemia
and  hyperferritinemia. The treatment needs to be started quickly, and the majority of
cases have a good response with corticosteroids and cyclosporine. The Epstein–Barr virus is
described as a possible trigger for many cases of MAS, especially in these patients in treat-
ment with tumor necrosis factor (TNF) blockers. In these refractory cases, etoposide (VP16)
should be administered, associated with corticosteroids and cyclosporine. Our objective is
to  describe a rare case of MAS probably due to EBV infection in a subject with systemic-
onset juvenile idiopathic arthritis, which achieved complete remission of the disease after
therapy guided by 2004-HLH protocol.
© 2014 Elsevier Editora Ltda. All rights reserved.
Síndrome  de  ativac¸ão macrofágica  em  paciente  com  artrite  idiopática
juvenil  sistêmica
r  e  s  u  m  oalavras-chave:
índrome hematofagocítica
írus Epstein-Barr
A síndrome de ativac¸ão macrofágica (SAM) é uma doenc¸a rara e potencialmente fatal,
normalmente associada às doenc¸as reumáticas crônicas, em especial a artrite idiopática
juvenil. É incluída no grupo das formas secundárias de síndrome hemofagocítica, cujas
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Artrite idiopática juvenil forma
sistêmica
Protocolo de tratamento HLH-04
outras causas podem ser as doenc¸as linfoproliferativas e infecc¸ões. As manifestac¸ões
clínicas e laboratoriais mais importantes são a febre não remitente, esplenomegalia,
hemorragias, disfunc¸ão hepática, citopenias, hipoalbuminemia, hipertrigliceridemia e
hiperferritinemia. O tratamento deve ser iniciado rapidamente, e a maioria dos casos
responde bem aos corticosteroides e à ciclosporina (CSA). O vírus Epstein-Barr (EBV) é
descrito como possível gatilho para muitos casos de SAM, especialmente naqueles em
tratamento com bloqueadores do fator de necrose tumoral (TNF). Nos casos refratários ao
tratamento convencional, etoposide (VP16) deve ser administrado, em associac¸ão com corti-
costeroides e CSA. Nosso objetivo foi descrever um caso raro de síndrome hematofagocítica
provavelmente secundária à infecc¸ão pelo vírus Epstein-Barr (EBV), em paciente com artrite
idiopática juvenil sistêmica, conﬁrmada pelas manifestac¸ões clínicas e laboratoriais típicas,
mielograma e sorologia positiva contra o EBV, que atingiu remissão completa após inclusão
no  protocolo de tratamento HLH-04.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare and
potentially fatal disease. Its annual incidence is 1:50,000 live-
born infants. It can be divided into two groups: primary and
secondary.
Macrophage activation syndrome (MAS) is a severe
complication of rheumatic diseases that occurs much
more frequently in patients with systemic juvenile idio-
pathic arthritis (SJIA). It is characterized by fever, hep-
atosplenomegaly, cytopenias, liver dysfunction, bleeding
diathesis and neurological symptoms, revealing a hetero-
geneous syndrome, which makes its detection harder. The
presence of macrophages actively phagocytosing hematopoi-
etic cells in the liver, spleen, bone marrow or lymph node
conﬁrms the diagnosis.1,2 The criteria formulated for HLH
2diagnosis (Table 1) may not be useful to deﬁne MAS. The
great challenge is to differentiate it from the exacerbation
of the underlying disease.1,3,4 The clinical manifestations of
Table 1 – Diagnostic criteria for hemophagocytic
lymphohistiocytosis (HLH).
A. Molecular diagnosis compatible with HLH: pathological mutations
of PRF1,  UNC13D,  Munc 18-2,  Rab27a, STX11, SH2D1A,  or BIRC 4
OR
B. 5 of the 8 criteria listed below:
1. Fever (temperature greater than 38.3 ◦C);
2. Splenomegaly;
3.  Cytopenias (involvement of at least 2 lineages)
3.1. Hemoglobin < 9 g/dL or <10 g/dL in newborns
3.2. Platelets < 100,000 mL
3.3. Neutrophils < 1000 mL;
4. Hypertriglyceridemia (>265 mg/dL) or hypoﬁbrinogenemia
(<150 mg/dL);
5. Hemophagocytosis in the bone marrow, spleen, lymph nodes or
liver – no evidence of malignancy;
6. Reduced or absent activity of NK cells;
7. Serum ferritin > 500 ng/dL;
8. Increase soluble CD25 (>2.400 U/mL)
Source: Histiocyte Society – Treatment Protocol of The Second Inter-
national HLH Study 2004.both showed 40% similarity.5 The pathogenesis of MAS  con-
sists of cytokine overproduction and exuberant inﬂammation,
leading to uncontrolled macrophage phagocytosis, antigen
presentation and persistent activation of T lymphocytes.6,7
Prevalence is more  often studied in SJIA patients, estimated
to be between 7% and 13%.3
MAS is included in the group of secondary forms of HLH,
whose causes are lymphoproliferative diseases, infections
(viral, bacterial, parasitic and fungal) and rheumatic diseases.
Genetic mutations, which compromise secretion of perforins,
are the main trigger in the primary form.
Our objective was to describe a case of MAS  probably due
to Epstein–Barr virus (EBV) infection and show how the appro-
priate treatment was essential for a favorable outcome.
Case  report
The patient is a 9-year-old girl diagnosed with SJIA since 2007,
taking prednisolone 9 mg/day (0.3 mg/kg/day), methotrexate
(MTX) 20 mg/week (0.6 mg/kg/week) and etanercept (ETN)
25 mg/week (0.8 mg/kg/week), with partially controlled dis-
ease. In December 2011, she presented fever, vomit, abdominal
pain, diarrhea and jaundice, evolving with impairment of
liver function, mucocutaneous bleeding, bicytopenia and hep-
atosplenomegaly. Upon hospital admission, she presented
anemia (Hb 8.1 g/dL), thrombocytopenia (57 × 103/L), elevated
serum liver enzyme levels (aspartate aminotransferase – AST
– 518 U/L and alanine aminotransferase – ALT – 121 U/L),
hypoalbuminemia (2.8 g/dL), coagulopathy (RNI 1,29), reduced
serum levels of ﬁbrinogen (94 mg/dL), increased triglycerides
(353 mg/dL) and ferritin (>1000 ng/mL). Serology for viral and
autoimmune hepatitis was negative. She received transfu-
sions of fresh frozen plasma that controlled the bleeding. A
bone marrow examination revealed hemophagocytosis (Fig. 1).
She was diagnosed with MAS and treated with 3 pulses
of methylprednisolone 30 mg/kg/day, followed by oral pred-
nisone (PDN) 2 mg/kg/day and cyclosporine (CSA) 2 mg/kg/day.
MTX and ETN were suspended. Her symptoms and clinical
signs did not improve despite the increase in CSA dose to
6 mg/kg/day. Fever was sustained and she maintained abnor-
mal  laboratory ﬁndings: bicytopenia (Hb 7.8 g/dL and platelets
r e v b r a s r e u m a t o l . 2
Fig. 1 – Hemophagocytosis in the bone marrow.
Credit:  Dr. Paulo do Val Rezende (Department of Pediatric
Hematology of Hospital das Clínicas of Universidade
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4 × 103/L), increased serum ferritin levels (>1.000 ng/mL),
levated triglycerides (445 mg/dL) and reduced ﬁbrinogen
96 mg/mL).
She developed sepsis after the initial treatment, worsening
er clinical and laboratory condition. In addition to antibi-
tics, intravenous human immunoglobulin (IVIG) 2 g/kg was
dministered, with no improvement.
After cytomegalovirus (CMV) and EBV serology results,
he latter positive IgM and IgG, and a lumbar puncture,
o rule out central nervous system (CNS) involvement, we
ecided in conjunction with the Hematology team, to start
LH-04 treatment protocol: dexamethasone, etoposide (VP
6), in addition to CSA, for eight weeks. After the fourth
eek of treatment protocol, there was febrile neutropenia
total leukocyte count 0.87 × 103/L), and hair rarefaction,
oth complications that were already expected with this
reatment.
The disease remitted after eight weeks. Her last labora-
ory assessment showed normalization of ferritin (270 ng/mL),
riglycerides (78 mg/dL), hemoglobin (13.7 g/dL), ﬁbrinogen
250 mg/mL), AST (23 U/L) and ALT (34 U/L). The patient is cur-
ently taking PDN 5 mg/day and CSA 6 mg/kg/day.
iscussion  and  conclusionhe purpose of this case report is motivating rheuma-
ologists to consider MAS  when faced with patients with
ever, hepatosplenomegaly, impairment of liver function
nd cytopenias, so treatment can be quickly initiated. It 0 1 5;5  5(1):79–82 81
is important to emphasize that the diagnosis of MAS  is
often a challenge as it may mimic  a ﬂare of the under-
lying disease. There are no validated criteria for diagnosis
of MAS.6 Ravelli et al.2 proposed diagnostic guidelines
for MAS complicating SJIA, based on expert consensus.
Clinical and laboratory ﬁndings that were more  sensi-
tive to MAS differentiation from ﬂares of the underlying
disease were selected. The most frequent ﬁndings were
thrombocytopenia, hyperferritinemia, elevated liver enzymes,
leukopenia, bone marrow hemophagocytosis, persistent fever,
drop in the erythrocyte sedimentation rate, hypoﬁbrino-
genemia and hypertriglyceridemia.2 In our patient, the
presence of bleeding, daily and non-remitting fever, pan-
cytopenia and reduced ﬁbrinogen serum levels stood out,
which led us to consider a diagnosis other than SJIA
activation.
We consider that there was a combination of triggers.
Immunosuppression with synthetic and biological drugs, per-
sistent disease activity, and EBV infection has contributed to a
severe and life-threatening disease. The SJIA therapy, mainly
MTX but also ETN,5,6 might have been the trigger. Biological
drugs have been described not only as a possible treatment
for MAS, but also as syndrome triggering factors.6
Currently, the treatment for macrophage activation syn-
drome is based on corticosteroids and CSA. CSA has proved
effective in patients with severe disease and corticosteroid
resistant,6,7 that is why it was introduced early in the treat-
ment. Human intravenous immunoglobulin is an alternative
therapy,6,8 also ineffective in our patient. There are a few
reports of effectiveness of interleukin-1 antagonists, partic-
ularly anakinra9 (unavailable in our country) in those patients
refractory to conventional treatment. Since the disease was
refractory to the initial therapy, we were motivated to look
for other causes, like the possible association with EBV infec-
tion, considered to be one of the major etiological agents and
responsible for the most severe cases.8,10,11 So we  chose the
treatment guided by the HLH-04 protocol. VP16 is important,
mainly, in refractory cases,6,8,11–13 and should be promptly ini-
tiated since it confers the most favorable prognosis in these
situations.11
The HLH treatment protocol was proposed in 1994 and
revised in 2004 for treatment of primary and secondary forms,
related to infections and malignancies. The speciﬁc infec-
tious treatment appears to have a result in cases of visceral
leishmaniasis, cytomegalovirus and bacterial infections, but
there is no beneﬁt described in disease associated with EBV
infection.9,10 The treatment was based on the dexamethasone
and VP16 association, in an eight-week induction period. In
case of remission, treatment should be suspended after eight
weeks.1,3,12 Otherwise, these patients should be referred to
stem cell transplantation.6,12
In summary, the importance of this report is, in addition
to the extensive discussion of possible triggers, the successful
treatment with etoposide, which was essential for induction of
remission of MAS. We also emphasize how often MAS  has been
diagnosed nowadays and question whether the immunobio-
logical therapy has implied an increase in the number of cases,
since it makes our patients more  vulnerable to opportunis-
tic infections of any etiology that is also considered to be a
predisposing factor for the disease.
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